Nuvation Bio Future Growth

NYSE:NUVB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	66	-209	N/A	N/A	2
12/31/2025	2	-174	N/A	N/A	4
12/31/2024	2	-556	N/A	N/A	5
9/30/2024	2	-532	N/A	N/A	N/A
6/30/2024	1	-511	-84	-84	N/A
3/31/2024	N/A	-69	-64	-64	N/A
12/31/2023	N/A	-76	-68	-68	N/A
9/30/2023	N/A	-83	-69	-69	N/A
6/30/2023	N/A	-90	-81	-81	N/A
3/31/2023	N/A	-105	-91	-91	N/A
12/31/2022	N/A	-104	-96	-96	N/A
9/30/2022	N/A	-108	-104	-103	N/A
6/30/2022	N/A	-103	-89	-88	N/A
3/31/2022	N/A	-88	-79	-78	N/A
12/31/2021	N/A	-87	-68	-68	N/A
9/30/2021	N/A	-75	-58	-58	N/A
6/30/2021	N/A	-64	-53	-53	N/A
3/31/2021	N/A	-53	-43	-43	N/A
12/31/2020	N/A	-42	-37	-37	N/A
9/30/2020	N/A	-38	-33	-33	N/A
6/30/2020	N/A	-32	-33	-32	N/A
3/31/2020	N/A	-33	-30	-29	N/A
12/31/2019	N/A	-34	-25	-24	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NUVB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NUVB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NUVB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NUVB's revenue (69.4% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: NUVB's revenue (69.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NUVB's Return on Equity is forecast to be high in 3 years time

Nuvation Bio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 7.1% to US$6.50

Price target increased by 9.4% to US$7.00

Price target increased by 9.5% to US$4.08

Price target decreased by 8.6% to US$3.73

Price target decreased to US$4.60

Price target decreased to US$4.60

Recent updates

Price target decreased by 7.1% to US$6.50

Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market

Insider recently bought US$220k worth of stock

Nuvation Bio Inc. Appoints Philippe Sauvage as Chief Financial Officer

Nuvation Bio Announces Positive Pooled Data from the Pivotal Phase 2 TRUST-I and TRUST-II Studies Evaluating Taletrectinib, an Investigational Next-Generation ROS1 TKI

New major risk - Shareholder dilution

Price target increased by 9.4% to US$7.00

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Is Nuvation Bio (NYSE:NUVB) A Risky Investment?

Nuvation Bio: A Potentially Transformative Acquisition

Independent Director recently bought US$500k worth of stock

New minor risk - Shareholder dilution

Nuvation Bio Inc. (NYSE:NUVB) completed the acquisition of AnHeart Therapeutics Ltd

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer

Price target increased by 9.5% to US$4.08

Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

New minor risk - Share price stability

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. Announces Resignation of Oleg Nodelman from Board of Directors

Nuvation Bio Inc. Appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer

Nuvation Bio Inc. Appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer

Nuvation Bio Announces Departure of Jennifer Fox as Chief Financial Officer, Effective November 27, 2023

Nuvation Bio Announces Departure of Jennifer Fox as Chief Financial Officer, Effective November 27, 2023

Price target decreased by 8.6% to US$3.73

New minor risk - Share price stability

Nuvation: Cash Is King, Science Is An Afterthought

We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

Nuvation Bio Inc. Announces Formation of Oncology-Focused Scientific Advisory Board

Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit

We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely

Nuvation Bio Inc. Doses First Patient in Phase 1B Combination Study of NUV-868

Independent Director recently bought US$484k worth of stock

Price target decreased to US$4.60

We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth

Price target decreased to US$4.60

Nuvation Bio GAAP EPS of -$0.12 beats by $0.02

Price target decreased to US$9.70

Nuvation Bio Inc. Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Inc. Appoints David Liu as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of Nuv-422 in Solid Tumors

Nuvation Bio Inc.(NYSE:NUVB) dropped from Russell 2000 Growth Index

Nuvation Bio Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$16.33

High number of new and inexperienced directors

Price target decreased to US$16.80

Nuvation Bio Inc. Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies